CHEMICON International, Inc. (SERO) Licenses Quantum Dot Antibody Reagent Line From Quantum Dot Corporation
10/19/2005 5:12:56 PM
ATLANTA & HAYWARD, Calif.--(BUSINESS WIRE)--March 4, 2005--Chemicon International, a subsidiary of Serologicals Corporation (NASDAQ: SERO), and Quantum Dot Corporation (QDC) today announced the signing of an agreement granting Chemicon rights to market specific quantum dot-containing products for the detection of antibody-antigen interactions in immunological experiments. This agreement will add novel secondary antibody detection technologies to Chemicon's general reagents product portfolio. Researchers will be able to use these products for the study of antigen presence in a variety of tissue and cell culture samples. Chemicon is recognized as a worldwide leader in providing specific antibodies, kits and ancillary reagents for the detection of antigen targets in the neuroscience, stem cell, cancer, in vitro diagnostics, and other fields. Chemicon will offer these products through its direct sales team in North America, Australia, UK and much of Europe, as well as through its worldwide network of distributors.
comments powered by